Senseonics Holdings, Inc. (SENS) Stock

Senseonics Holdings, Inc. (SENS) is a Technology stock trading at $8.81 (as of 2026-08-20), with a market capitalization of $368.49M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Senseonics Holdings, Inc. develops and commercializes continuous glucose monitoring systems for people with diabetes, including the Eversense and Eversense XL implantable platforms that measure glucose via an under-the-skin sensor and transmit data to an app through a removable, rechargeable smart transmitter. Its systems are sold in the United States, Europe, the Middle East, and Africa, serving patients through healthcare providers via distributor and fulfillment partner channels.

Understand Senseonics Holdings, Inc.: how it makes money

Senseonics develops and commercializes implantable continuous glucose monitoring (CGM) systems, including the Eversense and Eversense XL sensor plus a removable rechargeable smart transmitter and companion app, and makes money by selling these CGM systems to patients and healthcare providers.

For an implantable CGM, revenue growth and repeat demand depend on patient growth plus repeat cycles, which in turn require an operational insertion network (trained inserters, EonCare states and nurse capacity) and retention from Sensor One to Sensor Two.

Revenue by segment (latest quarter)
US	$0.0B
OutsideUS	$0.0B

Business quality (Weak): Key operating metrics are available (patient growth, covered lives, retention, insertion network), but the latest quarter shows revenue effectively near zero (0.0B, while segment candidates round to about 0.01B), and profitability is deeply negative.

Bull case

Scaling reach, via Additional Covered Lives for Eversense E3, ties directly to how many people can use the technology: Operational focus on covered lives suggests management is tracking whether the installed base is expanding enough to drive future revenue.
Repeat-cycle potential indicated by Sensor One to Sensor Two retention rate: A higher retention rate can support durability of future demand for subsequent sensors.

Bear case

Material operating losses: Operating margin is -271.9% in the latest reported period, which means the current revenue level and cost structure are not yet covering operating costs.
Insertion execution is a bottleneck for implantable CGM: Metrics tied to inserter training and capacity (New Trained Inserters Added, EonCare network size, EonCare nurses available) imply that insufficient insertion availability can limit patient adoption.
Revenue structure may be sensitive to consignment mechanics: Consignment Share of Revenue is tracked, which can signal that part of revenue recognition depends on product movement and sell-through timing.

Valuation — source: SEC EDGAR (first-party)
Price	$8.81
Market Cap	$368.49M
Price / Book	10.73
Price / Sales	9.05
FCF Yield	-22.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$35.26M
Net Margin	-196.0%
Revenue Growth (YoY)	87.2%
EPS Growth (YoY)	3450.0%
FCF Growth (YoY)	94.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	-8.51 (distress)
Piotroski F-Score	7/9 (strong)

Valuation vs Sector & Industry
Sector P/E (Technology)	33.9
Industry P/E (Measuring & Control Equipment)	51.8

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Sessa Capital IM, L.P. ($11.76M)
Institutional Holders Tracked	10

Company
Sector	Technology
Industry	Measuring & Control Equipment
CEO	Timothy T. Goodnow
Employees	117
Country	US
IPO Date	2015-12-22

Related Companies (Business model: Industrials / Capital Goods (Heavy Machinery + Diversified Industrials); 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.